Study guide
7.4 Conflict of Interest, Research Misconduct & Fraud in Clinical Research
ACRP Certified Professional ACRP-CP
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: GCP Principles, Roles & Delegation
1.1 The Eleven ICH E6(R3) Principles of GCP & Guideline Structure 1.2 Sponsor & Investigator Responsibilities and Delegation of Authority 1.3 Staff Training, Qualifications & Delegation of Authority Log (DOAL) 1.4 CRO Oversight, Vendor Management & Transfer of Regulatory Obligations (TORO)
2 Chapter 2: Essential Records, Source Documentation & Data Confidentiality
2.1 Essential Records Before, During and After the Trial (ICH E6(R3) Appendix C) 2.2 Trial Master File (TMF) and Investigator Site File (ISF) Structure & Inspection Readiness 2.3 Source Documentation, ALCOAC Principles & Medical Record Standards 2.4 Confidentiality, Privacy & Protection of Participant Personal Information
3 Chapter 3: Monitoring, Quality Management & Audits
3.1 Risk-Based Quality Management (RBQM) & Quality Management Systems (QMS) 3.2 Monitoring Visit Types: Site Selection, SIV, IMV, and Close-Out 3.3 Risk-Based Monitoring (RBM), Centralized Monitoring & Source Data Verification (SDV vs SDR) 3.4 Quality Audits, Regulatory Inspections, Non-Compliance & Root Cause Analysis / CAPA
4 Chapter 4: Site Feasibility, Start-Up, Facilities & Laboratory Operations
4.1 Site Feasibility Assessment, Capability Analysis & Investigator Selection 4.2 Contractual Agreements: Clinical Trial Agreements, Budgets, Indemnification & Financial Arrangements 4.3 Site Initiation Preparation, System Access & Regulatory Greenlight 4.4 Protocol Review, Operational Feasibility & Institutional Approvals 4.5 Site Facilities, Equipment Maintenance, Calibration & Trial Supplies 4.6 Biological Samples & Hazardous Goods: Collection, Storage, Disposal & Shipment
5 Chapter 5: Subject Recruitment, Retention & Study Visits
5.1 Subject Recruitment Strategies, Advertising Guidelines & Ethical Constraints 5.2 Screening, Eligibility Verification & Inclusion/Exclusion Adherence 5.3 Subject Retention, Compliance, Visit Scheduling & Protocol Window Management 5.4 Managing Lost to Follow-Up, Subject Withdrawal & Early Termination Procedures
6 Chapter 6: Protocol Compliance, Deviations & Site Close-Out
6.1 Protocol Compliance, Waivers vs. Violations & Deviation Management 6.2 Investigational Site Close-Out Activities & Final Reconciliations 6.3 Record Retention, Archiving Requirements & Post-Trial Responsibilities
7 Chapter 7: Research Ethics, Vulnerable Populations & Research Integrity
7.1 Historical Milestones: Nuremberg Code, Belmont Report & Declaration of Helsinki 7.2 Ethical Principles: Beneficence, Non-Maleficence, Autonomy, Justice & Equipoise 7.3 Vulnerable Populations (Pediatrics, Pregnant Women, Prisoners, Cognitively Impaired, Economically Disadvantaged) 7.4 Conflict of Interest, Research Misconduct & Fraud in Clinical Research
8 Chapter 8: Informed Consent & Institutional Review Boards (IRB/IEC)
8.1 Informed Consent Elements, Process & Ongoing Consent / Re-Consent Requirements 8.2 Assent in Minors & Legally Acceptable Representative (LAR) Requirements 8.3 IRB/IEC Composition, Functions, Review Types (Full, Expedited, Exempt) & Continuing Review
9 Chapter 9: Safety Reporting & Adverse Event Management (ICH E2A)
9.1 Adverse Events (AE) vs. Adverse Drug Reactions (ADR) & Serious Adverse Events (SAE) Definitions 9.2 Causality Assessment, Expectedness, Reference Safety Information (RSI) & SUSARs 9.3 Expedited Reporting Timelines (7-day fatal/life-threatening, 15-day other serious) & Periodic Safety Updates (DSUR)
10 Chapter 10: Investigational Product (IP) Management & Accountability
10.1 Investigational Product Lifecycle, Labeling, Packaging & Blinding Procedures 10.2 IP Shipping, Receipt, Temperature Monitoring, Excursion Handling & Chain of Custody 10.3 IP Storage, Dispensing, Accountability Logs & Destruction/Return Procedures 10.4 Emergency Unblinding (Code Breaking) Protocols & Subject Safety Procedures
11 Chapter 11: Regulatory Frameworks, Submissions & Product Reference Information
11.1 Stakeholders, Regulatory Institutions & Global Frameworks in Clinical Research 11.2 Protocol Submission, Approval & Amendment Processes 11.3 Investigator's Brochure, Instructions for Use & Reference Product Information 11.4 Regulatory Reporting Requirements Before and After Marketing Authorisation
12 Chapter 12: Clinical Data Management, EDC & Electronic Records
12.1 Electronic Data Capture (EDC), eCRF Design & Clinical Data Management Systems (CDMS) 12.2 Computerised Systems, Data Governance & Audit Trails (ICH E6(R3) Annex 1 §4) 12.3 Data Validation, Edit Checks, Discrepancy / Query Management & Resolution 12.4 Medical Coding (MedDRA, WHO Drug), SAE Reconciliation, Data Transfer & Database Lock
13 Chapter 13: Trial Design, Biostatistics, Data Monitoring & Transparency
13.1 Phases of Clinical Research (Phase 0, I, II, III, IV) & Translational Medicine 13.2 Study Designs: Parallel, Crossover, Factorial, Adaptive & Non-Inferiority / Equivalence 13.3 Randomization Schemes, Stratification, Blinding Methods & Minimizing Bias 13.4 Endpoints (Primary, Secondary, Surrogate, Composite), Sample Size & Biostatistical Concepts (p-values, CI, ITT vs PP) 13.5 Interim Analyses, DSMB/IDMC Oversight & Efficacy and Safety Evaluation Milestones 13.6 Trial Registration, Results Transparency & Communicating Results to Participants
7.4 Conflict of Interest, Research Misconduct & Fraud in Clinical Research
Key Takeaways Explain This Topic AI
A conflict of interest is a situation, not an act — it exists as soon as a secondary interest could bias professional judgement, whether or not anyone has actually behaved improperly.
The 2024 Declaration of Helsinki requires sources of funding and potential conflicts of interest to be stated in the protocol (paragraph 22) and disclosed to potential participants during consent (paragraph 26).
ICH E6(R3) Annex 1 section 3.9.9 requires committees affecting participant safety or result reliability to have relevant expertise, managed conflicts of interest, written charters and documented decisions.
Research misconduct is conventionally defined as fabrication, falsification or plagiarism; honest error and legitimate scientific disagreement are explicitly excluded.
Serious noncompliance triggers root cause analysis, corrective and preventive action, and notification of the regulatory authority and/or IRB/IEC under ICH E6(R3) Annex 1 section 3.12.
Last updated: August 2026
Conflict of Interest, Research Misconduct & Fraud
Quick Reference: A conflict of interest is a circumstance in which a secondary interest — money, career advancement, personal relationship, institutional loyalty — could reasonably be seen to compromise judgement about a primary interest, which in clinical research is participant welfare and the reliability of results. Misconduct is an act . Conflicts are disclosed and managed; misconduct is investigated and sanctioned. Confusing the two is the most common exam error in this area.
Why this is tested
The ACRP-CP Exam Content Outline lists 1N, "Conflict of interest in clinical research" and 1O, "Fraud and misconduct" as separate knowledge statements in Domain 1, and includes the task statements "Evaluate potential conflicts of interest" and "Identify, investigate, and report potential fraud and misconduct."
- Part 1 — Conflict of interest
- A conflict exists before anyone does anything wrong
The test is whether a reasonable observer would judge that the secondary interest could bias the primary judgement , not whether bias actually occurred. An investigator holding equity in the sponsor has a conflict on the day the trial opens, even if every subsequent decision is impeccable. This is why "I would never let it affect me" is never an adequate response — it answers a question nobody asked.
Financial and non-financial conflicts
Type Examples
Financial — investigator Equity or stock options in the sponsor; consultancy or advisory board fees; speaker honoraria; paid patents or royalties on the product; per-participant payments substantially exceeding the cost of the work
Financial — institutional Institutional equity holdings; large philanthropic gifts from the sponsor; departmental revenue dependence on a trial portfolio
Non-financial — professional Authorship and publication ambition; promotion or tenure tied to recruitment; a strong prior public position on the therapy
Non-financial — personal Enrolling one's own patients, students, employees or family members; a close relationship with the sponsor's medical monitor
Dual role The treating physician who is also the investigator — the archetypal conflict, because the participant may not distinguish the two roles
Exam Watchout: The dual role of clinician and investigator is the conflict the exam returns to most. It is not prohibited — it is normal and often necessary — but it must be managed, usually by having someone other than the treating physician conduct the consent discussion so the participant does not feel that declining will damage their care. It also underlies therapeutic misconception , discussed in section 7.2.
What the source documents require
Source Requirement
Declaration of Helsinki (2024), paragraph 22 The protocol should include sources of funding and any potential conflicts of interest
Declaration of Helsinki (2024), paragraph 26 Potential participants must be informed of sources of funding and any potential conflicts of interest during the consent process
ICH E6(R3) Annex 1, 3.9.9 Committees whose work could affect participant safety or the reliability of results must have relevant expertise, managed conflicts of interest , written operating procedures such as charters, and documented decisions
IRB/IEC practice A member with a conflicting interest in a specific trial must not participate in the deliberation or vote on that trial; the recusal is minuted
The disclose → assess → manage sequence 1. DISCLOSE Investigator, sub-investigators and key staff declare interests
- to the institution, the sponsor and the IRB/IEC — at start-up
- and whenever circumstances change
- │
- 2. ASSESS Institutional COI committee / IRB/IEC judge whether the interest
- could reasonably bias the trial
- │
3. MANAGE Choose a proportionate control:
- Disclose in the consent form and in publications
- Independent consent-taker
- Independent adjudication of endpoints
- Reduce or divest the financial interest
- Recuse from specific decisions
- In the extreme: the individual does not take the role
- │
- 4. MONITOR Re-declare periodically; changes are reported, not assumed benign
Disclosure alone is management only for minor interests. A significant equity stake is not neutralised by a sentence in a consent form.
- Part 2 — Research misconduct and fraud
- The standard definition
Research misconduct is conventionally defined as fabrication, falsification or plagiarism in proposing, performing or reviewing research, or in reporting results:
Term Definition Clinical trial example
Fabrication Making up data or results and recording or reporting them Recording vital signs for a visit the participant never attended; inventing a participant entirely
Falsification Manipulating materials, equipment or processes, or changing or omitting data such that the research is not accurately represented Back-dating a consent form; altering a laboratory value to bring a participant inside the eligibility range; deleting an adverse event
Plagiarism Appropriating another's ideas, processes, results or words without credit Copying another site's source note template complete with its clinical content
Honest error and differences of scientific opinion are expressly not misconduct. A transcription mistake corrected through the audit trail is a data quality issue, not fraud. The distinguishing feature of misconduct is intent to deceive .
Related integrity failures
Eligibility gaming — repeating a screening test until a value falls in range without protocol authorisation, or omitting a documented exclusion.
Consent violations — signing on behalf of a participant, consenting after procedures have begun, using a superseded consent version knowingly.
Ghost or guest authorship and selective reporting of favourable outcomes.
Financial fraud — invoicing the sponsor for visits or procedures that did not occur.
Signals that surface fraud
Fraud is usually detected through patterns , not confessions. Central and centralised monitoring exists partly for this reason:
Signal Why it is suspicious
Data too clean No missing values, no out-of-range results, implausibly low variability compared with other sites
Digit preference Blood pressures ending in 0, weights rounded uniformly
Impossible timings Multiple participants' visits documented at the same minute; procedures logged outside clinic hours
Identical handwriting or signature style across participants' diaries Diaries completed by staff rather than participants
Enrolment far above every other site , with no demographic explanation Eligibility criteria may not be being applied
- Consent dates after the first protocol procedure Procedures performed before consent
- Source records that appear all at once Records recreated retrospectively for a monitoring visit
- Audit trail anomalies Bulk edits by one user shortly before a visit; disabled audit trail
Exam Watchout: The correct action on suspicion is preserve, report, do not confront . A coordinator or monitor who challenges the suspected individual directly risks the destruction of evidence and may compromise a formal investigation. Secure the records — including electronic audit trails — and escalate through the defined route.
Escalation under ICH E6(R3)
Annex 1 section 3.12 sets out the pathway, and it distinguishes ordinary from serious noncompliance:
Section Requirement
3.12.1 Noncompliance by an investigator, institution or sponsor staff should lead to appropriate and proportionate action by the sponsor to secure compliance
3.12.2 Where noncompliance significantly affects, or could significantly affect, participants' rights, safety or well-being or the reliability of results , the sponsor performs a root cause analysis , implements CAPA and confirms its adequacy. Such serious noncompliance is notified to the regulatory authority and/or IRB/IEC as applicable
3.12.3 Where significant noncompliance persists despite remediation , the sponsor should consider terminating the investigator's, institution's or service provider's participation, promptly notify authorities and the IRB/IEC, and act to minimise the impact on participants and on the reliability of results
Principle 6.3 sits behind all of this: strategies must avoid, detect, address and prevent recurrence of serious noncompliance. Detection is an obligation, not a matter of luck.
Realistic exam scenario
Scenario: A monitor performing source data verification at a high-enrolling site notices that eight participants' diary cards are completed in what appears to be the same handwriting and ink, that all eight report exactly 100% dosing compliance, and that four have identical free-text comments. The site's principal investigator is also the participants' treating cardiologist, holds share options in the sponsor that were declared to the institution but do not appear in the consent form, and receives a per-participant payment noticeably higher than the visit workload appears to justify.
Evaluation — two distinct problems that must not be merged:
The conflict of interest is a disclosure and management failure. Under the 2024 Declaration of Helsinki, funding sources and potential conflicts belong in the protocol (paragraph 22) and must be disclosed to participants during consent (paragraph 26). The share options were declared institutionally but not to participants, and the dual clinician–investigator role compounds the problem. This is remedied by amending the consent form with IRB/IEC approval, introducing an independent consent-taker, and having the institution's COI committee reassess the arrangement — including whether the per-participant payment is justifiable against actual effort.
The diary cards are a possible misconduct signal — identical handwriting, implausible perfection and duplicated free text together suggest fabrication . This is not resolved by disclosure.
Correct actions: do not confront the investigator or site staff. Preserve the diary cards and secure the relevant electronic audit trails. Escalate immediately to the sponsor per the monitoring plan and the site's misconduct procedure. Expect the sponsor to perform a root cause analysis and, if the finding is confirmed as serious noncompliance under 3.12.2, to notify the regulatory authority and/or IRB/IEC, implement CAPA, assess the reliability of that site's data for the analysis, and consider whether participants were placed at risk. If the noncompliance persists after remediation, 3.12.3 puts termination of the site on the table. Handle the conflict of interest through its own disclosure and management track in parallel.